Spago Nanomedical AB (publ) (SPAGO.ST)
Spago Nanomedical AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $0.10, up 2.29% on the session, giving a market capitalisation of $78.4M. Its beta of 1.30 implies it has historically moved more than the broad market.
Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.
Spago Nanomedical AB (publ) is most often compared with the following Healthcare names: